In a groundbreaking move, Morocco’s Competition Council has greenlit the acquisition of the pharmaceutical giant Afric-Phar by the Sefrioui Group. The deal, valued at a staggering 2 billion dirhams (approximately €182 million), signals a bold leap into the pharmaceutical sector for Sefrioui, a company previously renowned for its real estate and construction material ventures.
The transaction, executed through Pharma Capital SA—a subsidiary of the Sefrioui Group—grants the conglomerate full control over Afric-Phar and its key subsidiaries, Pharmis and Partner Lab. These subsidiaries specialize in pharmaceutical production, distribution, and research and development, respectively. Afric-Phar stands as a cornerstone of Morocco’s pharmaceutical industry, employing close to 400 professionals and managing a robust portfolio of 200 products. These products cater to critical fields such as cardiology, anesthesiology, and central nervous system disorders.
In 2023, Afric-Phar, along with Pharmis and Partner Lab, reported a combined revenue of 784 million dirhams. This acquisition significantly enhances Sefrioui Group’s footprint in the pharmaceutical landscape, positioning it as a key player in a strategic and fast-evolving sector.
The deal, facilitated by Emerge Invest, underscores the Sefrioui Group’s ambitions to bolster Morocco’s pharmaceutical industry while contributing to the country’s healthcare sovereignty. By integrating Afric-Phar’s expertise, the group aims to drive innovation, boost local production capacity, and reduce reliance on imported medical products.
